School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia.
Hum Immunol. 2010 Dec;71(12):1214-9. doi: 10.1016/j.humimm.2010.09.001. Epub 2010 Sep 18.
Polymorphisms in the central major histocompatibility complex (MHC) are associated with several immunopathologic and inflammatory diseases, including chronic venous leg ulcers (CVLU). Because of strong linkage disequilibrium, identification of loci affecting disease susceptibility must be based on comparisons between haplotypes. Here we examine the association of conserved tumor necrosis factor (TNF) block haplotypes with CVLU susceptibility. A total of 171 Caucasian patients with CVLU were compared with 173 age-/gender-matched controls, excluding individuals with type 1 diabetes or rheumatoid arthritis. A total of 194 healthy subjects formed a separate population-based control group. Samples were typed for 38 tumor necrosis factor (TNF) block single nucleotide polymorphisms (SNP), human leukocyte antigen (HLA)-B and HLA-DRB1 alleles. TNF haplotypes were derived using the PHASE algorithm and assigned numbers (FVx) defined previously. The patients and matched controls shared 16 TNF block haplotypes. The patients had increased carriage of FV16 and alleles of the 8.1 and 60.3 MHC ancestral haplotypes (AH). CVLU risk is modulated by alleles within FV16 (e.g., TNF-308A and BAT1intron10 C insertion) or near FV16 in the 8.1AH. CVLU risk may also be mediated by unidentified alleles (not in FV22) marked by HLA-B40 and HLA-DR13. FV16 appears to be the best MHC and TNF block marker of susceptibility. After disease onset, an individual's TNF block haplotype does not modulate CVLU severity.
多态性在中央主要组织相容性复合体 (MHC) 与几种免疫病理和炎症性疾病有关,包括慢性静脉性腿部溃疡 (CVLU)。由于强烈的连锁不平衡,鉴定影响疾病易感性的基因座必须基于单体型之间的比较。在这里,我们研究了保守肿瘤坏死因子 (TNF) 阻断单体型与 CVLU 易感性的关联。总共比较了 171 例白种人 CVLU 患者与 173 例年龄/性别匹配的对照,排除了 1 型糖尿病或类风湿关节炎患者。共有 194 名健康受试者组成了一个独立的基于人群的对照组。对 38 个肿瘤坏死因子 (TNF) 阻断单核苷酸多态性 (SNP)、人类白细胞抗原 (HLA)-B 和 HLA-DRB1 等位基因进行了分型。TNF 单体型使用 PHASE 算法推导,并分配了以前定义的数字 (FVx)。患者和匹配的对照共享 16 个 TNF 阻断单体型。患者携带 FV16 和 8.1 和 60.3 MHC 祖先单体型 (AH) 的等位基因增加。FV16 内的等位基因 (例如 TNF-308A 和 BAT1 内含子 10 C 插入) 或 8.1AH 附近的等位基因调节 CVLU 风险。FV16 附近的未知等位基因 (不在 FV22 中) 可能通过 HLA-B40 和 HLA-DR13 标记调节 CVLU 风险。FV16 似乎是 MHC 和 TNF 阻断易感性的最佳标志物。疾病发作后,个体的 TNF 阻断单体型不会调节 CVLU 的严重程度。